title: Trajectories of entering the metabolic syndrome: the framingham heart study.
abstract: BACKGROUND
  We evaluated the progression of the metabolic syndrome (MetS) and its components, the trajectories followed by individuals entering MetS, and the manner in which different trajectories predict cardiovascular disease and mortality.
  
  
  RESULTS
  Using data from 3078 participants from the Framingham Offspring Study (a cohort study) who attended examinations 4 (1987), 5 (1991), and 6 (1995), we evaluated the progression of MetS and its components. MetS was defined according to the Adult Treatment Panel III criteria. Using logistic regression, we evaluated the predictive ability of the presence of each component of the MetS on the subsequent development of MetS. Additionally, we examined the probability of developing cardiovascular disease or mortality (until 2007) by having specific combinations of 3 that diagnose MetS. The prevalence of MetS almost doubled in 10 years of follow-up. Hyperglycemia and central obesity experienced the highest increase. High blood pressure was most frequently present when a diagnosis of MetS occurred (77.3%), and the presence of central obesity conferred the highest risk of developing MetS (odds ratio, 4.75; 95% confidence interval, 3.78 to 5.98). Participants who entered the MetS having a combination of central obesity, high blood pressure, and hyperglycemia had a 2.36-fold (hazard ratio, 2.36; 95% confidence interval, 1.54 to 3.61) increase of incident cardiovascular events and a 3-fold (hazard ratio, 3.09, 95% confidence interval, 1.93 to 4.94) increased risk of mortality.
  
  
  CONCLUSIONS
  Particular trajectories and combinations of factors on entering the MetS confer higher risks of incident cardiovascular disease and mortality in the general population and among those with MetS. Intense efforts are required to identify populations with these particular combinations and to provide them with adequate treatment at early stages of disease.
authors.affiliation: Unilever Corporate Research, Sharnbrook, UK. O.H.Franco@warwick.ac.uk
authors.forename: Oscar H
authors.initials: OH
authors.lastname: Franco
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Massaro
authors.forename: Jacky
authors.initials: J
authors.lastname: Civil
authors.forename: Mark R
authors.initials: MR
authors.lastname: Cobain
authors.forename: Brendan
authors.initials: B
authors.lastname: O'Malley
authors.forename: Ralph B
authors.initials: RB
authors.lastname: D'Agostino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000097:blood / Q000401:mortality*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000401:mortality; D008297:Male; D008404:Massachusetts / Q000453:epidemiology; D024821:Metabolic Syndrome / Q000097:blood / Q000401:mortality*; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000401:mortality*; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult